Von Willebrand factor in high-purity factor VIII complex concentrates: Chaperone protein or key to therapies? A meeting report

Haemophilia

Volumn 14, Issue 1, 2008, Pages 133-139

  Federici, Augusto B ^a   Mannucci, P M ^a   Marco, P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CHAPERONE; DESMOPRESSIN ACETATE; FANHDI; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8 CONCENTRATE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ABSENCE OF SIDE EFFECTS; ANTIGEN PRESENTING CELL; BLOOD DONOR; BOVINE SPONGIFORM ENCEPHALOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CREUTZFELDT JAKOB DISEASE AGENT; DENDRITIC CELL; DIAGNOSTIC TEST; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; DRUG SAFETY; ENDOCYTOSIS; GENETIC RISK; HEMOPHILIA; HEMOSTASIS; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; LOADING DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SECONDARY PREVENTION; SURGICAL PATIENT; T LYMPHOCYTE ACTIVATION; VIRUS TRANSMISSION; VON WILLEBRAND DISEASE;

FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MOLECULAR CHAPERONES; PREMEDICATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 37749001670     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01558.x     Document Type: Conference Paper

References (44)

1. Ironside JW. Variant Creutzfeldt-Jakob disease: Risk of transmission by blood transfusion and blood therapies. Haemophilia 2006; 12 (Suppl. 1): 8-15.
2. Prusiner SB. Biology and genetics of prion diseases. Annu Rev Microbiol 1994; 48: 655-86.
3. Smith PG, Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 2003; 66: 185-98.
4. Priola SA, Vorberg I. Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies. Methods Mol Biol 2004; 268: 517-40.
5. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. In: Treatment of Hemophilia. September, 2004. no. 34.
6. Darby SC, Keeling DM, Spooner RJ et.al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
7. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 436-63.
8. Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-8.
9. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
10. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
11. Astermark J, Oldenburg J, Carlson J et.al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
12. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
13. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
14. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
15. Sharathkumar A, Lillicrap D, Blanchette VS et.al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
16. von Auer C, Oldenburg J, von Depka M et.al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
17. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: A multi-center cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
18. Santagostino E, Mannucci PM. Protective effect of prophylaxis on inhibitor development in children with hemophilia A: More convincing studies are required. Response to Calvez and Laurian. Br J Haematol 2006; 132: 800-1.
19. Chalmers EA, Brown SA, Keeling D et.al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
20. Goudemand J, Rothschild C, Demiguel V et.al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
21. Dasgupta S, Repesse Y, Bayry J et.al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
22. Lin Y, Yang X, Chevrier MC et.al. Relationships between factor VIII:AG and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
23. Federici AB. The factor VIII/von Willebrand factor complex: Basic and clinical issues. Haematologica 2003; 88: EREP02.
24. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
25. Mariani G, Kroner B. International Immune Tolerance Registry, 1997 update. Vox Sang 1999; 77 (Suppl. 1): 25-7.
26. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
27. Kreuz W, Escuriola-Ettingshausen C, Auerswald G. Immune tolerance induction in haemophilia A patients with inhibitors: The choice of concentrate affecting success. Haematologica 2001; 86 (Suppl. 4): 16-20.
28. Orsini F, Rothschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
29. Gringeri A, Musso R, Mazzucconi MG et.al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
30. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
31. Berntorp E, Nilsson IM. Immune tolerance and the immune modulation protocol. Vox Sang 1996; 70 (Suppl. 1): 36-41.
32. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
33. Salvagno GL, Astermark J, Ekman M et.al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
34. Astermark J, Voorberg J, Lenk H et.al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
35. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years 'Bonn protocol'. Vox Sang 1996; 70 (Suppl. 1): 30-5.
36. Heisel Kurth M, Christie B, Hanneman V et al. Role of von Willebrand factor in immune tolerance induction. Abstract presented at the American Society of Hematology meeting in San Diego, CA, December, 2004.
37. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.
38. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-93.
39. Tosetto A, Rodeghiero F, Castaman G et.al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
40. Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease-single center comparison of four different assays. Thromb Haemost 2000; 84: 1127-8.
41. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost 2006; 4: 2088-90.
42. Schneppenheim R. The evolving classification of von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 1): S3-10.
43. Federici AB, Gianniello F, Mannucci PM. Secondary long-term prophylaxis in von Willebrand disease: An Italian cohort study. Haematol Rep 2005; 1: 15-20.
44. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 1): S23-6.